Vera Therapeutics, Inc. (VERA) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -1224.0%, revenue growth -15.4% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $24.48M |
| Revenue (TTM) | $0.0B |
| Net Margin | -1224.0% |
| Return on Equity | -98.6% |
| Operating Margin (TTM) | -1811.1% |
| Debt / Equity | 0.18 |
| Current Ratio | 10.92 |
| Net Debt / EBITDA | 1.0 |
| Interest Coverage | -55.2 |
| Revenue Growth (YoY) | -15.4% |
| EPS Growth (YoY) | 26.7% |
| FCF Growth (YoY) | 82.3% |
| Price / Book | 6.18 |
| Price / Sales | 109.73 |
| FCF Yield | -13.5% |
| Altman Z-Score | 8.66 (safe) |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
VERA overview · VERA earnings · VERA KPIs · VERA documents · VERA ownership · VERA peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.